AVBP vs AVTX: fair value comparison
ArriVent BioPharma, Inc. Common Stock and Avalo Therapeutics, Inc. · Updated 2026-10-19
AVBP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. AVTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AVBP currently ranks higher by quality score.
| AVBP | AVTX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $16.66 | $11.27 |
| 12-month range | $15.09–$34.74 | $11.27–$22.87 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #220 of 301 Healthcare | #222 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AVBP fair value analysis · AVTX fair value analysis